Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-21
2011-06-21
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C536S024100, C536S024500
Reexamination Certificate
active
07964578
ABSTRACT:
This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5334711 (1994-08-01), Sproat
patent: 5416016 (1995-05-01), Low et al.
patent: 5589332 (1996-12-01), Shih et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5631359 (1997-05-01), Chowrira et al.
patent: 5631360 (1997-05-01), Usman et al.
patent: 5633133 (1997-05-01), Long et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5716824 (1998-02-01), Beigelman et al.
patent: 5741679 (1998-04-01), George et al.
patent: 5792847 (1998-08-01), Buhr et al.
patent: 5804683 (1998-09-01), Usman et al.
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5831071 (1998-11-01), Usman et al.
patent: 5834186 (1998-11-01), George et al.
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5871914 (1999-02-01), Nathan et al.
patent: 5898031 (1999-04-01), Crooke
patent: 5989912 (1999-11-01), Arrow et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6001311 (1999-12-01), Brennan
patent: 6005087 (1999-12-01), Cook et al.
patent: 6008400 (1999-12-01), Scaringe et al.
patent: 6054576 (2000-04-01), Bellon et al.
patent: 6107094 (2000-08-01), Crooke
patent: 6111086 (2000-08-01), Scaringe et al.
patent: 6117657 (2000-09-01), Usman et al.
patent: 6153737 (2000-11-01), Manoharan et al.
patent: 6162909 (2000-12-01), Bellon et al.
patent: 6168778 (2001-01-01), Janjic et al.
patent: 6303773 (2001-10-01), Bellon et al.
patent: 6335434 (2002-01-01), Guzaev et al.
patent: 6353098 (2002-03-01), Usman et al.
patent: 6362323 (2002-03-01), Usman et al.
patent: 6395492 (2002-05-01), Manoharan et al.
patent: 6437117 (2002-08-01), Usman et al.
patent: 6469158 (2002-10-01), Usman et al.
patent: 6476205 (2002-11-01), Buhr et al.
patent: 6482932 (2002-11-01), Beigelman et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6528631 (2003-03-01), Cook et al.
patent: 7037646 (2006-05-01), Cook et al.
patent: 2003/0191075 (2003-10-01), Cook et al.
patent: 2004/0110296 (2004-06-01), Vargeese et al.
patent: 2004/0192626 (2004-09-01), McSwiggen et al.
patent: 2359180 (2000-08-01), None
patent: 0 360 257 (1990-02-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/02949 (1989-03-01), None
patent: WO 90/12096 (1990-10-01), None
patent: WO 90/14090 (1990-11-01), None
patent: WO 91/03162 (1991-03-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 93/15187 (1993-08-01), None
patent: WO 93/23569 (1993-11-01), None
patent: WO 94/01550 (1994-01-01), None
patent: WO 95/06731 (1995-03-01), None
patent: WO 95/11304 (1995-04-01), None
patent: WO 95/11910 (1995-05-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96-10392 (1996-04-01), None
patent: WO 96-22689 (1996-08-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/13526 (1998-04-01), None
patent: WO 98/27104 (1998-06-01), None
patent: WO 98/28317 (1998-07-01), None
patent: WO 98/43993 (1998-10-01), None
patent: WO 98/58058 (1998-12-01), None
patent: WO 99/07409 (1999-02-01), None
patent: WO 99/16871 (1999-04-01), None
patent: WO 99/17120 (1999-04-01), None
patent: WO 99/29842 (1999-06-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/49029 (1999-09-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/54459 (1999-10-01), None
patent: WO 99/55857 (1999-11-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 99/66063 (1999-12-01), None
patent: WO 00/01846 (2000-01-01), None
patent: WO 00/24931 (2000-05-01), None
patent: WO 00/26226 (2000-05-01), None
patent: WO 00/44895 (2000-06-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 00/49035 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/96584 (2001-12-01), None
patent: WO 02/22636 (2002-03-01), None
patent: WO 02/15876 (2002-05-01), None
patent: WO02/096927 (2002-12-01), None
patent: WO03/028764 (2003-04-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO2004/061081 (2004-07-01), None
Yuan et al., “Targeted cleavage of mRNA by human RNase P,” Proc. Nat!. Acad. Sci. USA 89:8006-8010 (1992).
Zarrinkar et al., “The P9.1-P9.2 peripheral extension helps guide folding of theTetrahymenaribozyme,” Nucl. Acids Res. 24:854-858 (1996).
Zimmerly et al., “A Group Illntran RNA is a Catalytic Component of a DNA Endonuclease Involved in Intran Mobility,” Cell 83:529-538 (1995).
Office Action mailed on Nov. 7, 2006 for U.S. Appl. No. 10/780,447, 4 pages.
Office Action mailed on Jul. 13, 2007 for U.S. Appl. No. 10/780,447, 11 pages.
2006 Chemical Abstracts Service Catalog, published by Chemical Abstracts Service, p. 52.
Ruoslahti, “RGD and Other Recognition Sequences for Integrins,” Annu. Rev. Cell Dev. Biol. 12:697-715 (1996).
Salo et al., “Aminooxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support,” Bioconjugate Chem.10:815-823 (1999).
Sanghvi et al., “Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator,” Org. Proc. Res. & Dev. 4:175-181 (2000).
Santoro et al., “A general purpose RNA-cleaving DNA enzyme,” Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997).
Santoro et al., “Mechanism and Utility of an RNA-Cleaving DNA Enzyme,” Biochem. 37:13330-13342 (1998).
Santoro et al., “RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality,” J. Am. Chem. Soc. 122:2433-2439 (2000).
Saville et al., “A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA inNeurosporaMitochondria,” Cell 61:685-696 (1990).
Saville et al., “RNA-Mediated Ligation of Self-Cleavage Products of aNeurosporaMitochondrial Plasmid Transcript,” Proc. Natl. Acad: Sci. USA 88:8826-8830 (1991).
Scaringe et al., “Chemical synthesis of biologically active oligoribonucleotides using (3-cyanoethyl protected ribonucleoside phosphoramidites,” Nucl. Acids Res. 18:5433-5441 (1990).
Schmajuk et al., “Antisense Oligonucleotides with Different Backbones,” J.Biol. Chem. 274:21783-21789 (1999).
Schmidt et al., “Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure,” Nucl. Acids Res. 24:573-581 (1996).
Schwarz et al., IlEvidence that siRNAs Function as Guides, Not Primers, in theDrosophilaand Human RNAi Pathways, Mol. Cell 10:537-548 (2002).
Schwarze et al., “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,” Science 285:1569-1572 (1999).
Scott et al., “The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage,” Cell 81:991-1002 (1995).
Seela et al., “Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute,” Nucl. Acids Res. 15:3113-3129 (1987).
Shabarova et al., “Chemical ligation of DNA: The first non-enyzmaticassembly of a biologically active gene,” Nucl. Acids Res. 19:4247-4251 (1991).
Sharp et al., “RNAi and double-strand RNA,” Genes & Dev. 13:139-141 (1999).
Silverman et al., “Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric O
Chen Tongqian
Haeberli Peter
Vargeese Chandra
Wang Weimin
Leff Matthew A.
Muthard David A.
Olson Eric S
Sirna Therapeutics, Inc.
LandOfFree
Conjugates and compositions for cellular delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates and compositions for cellular delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates and compositions for cellular delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694176